News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

CPS Innovations Granted Expansion Of Patent For PET/CT Scanner

10/19/2005 5:09:18 PM

KNOXVILLE, Tenn., Dec. 1 /PRNewswire-FirstCall/ -- CPS Innovations, a unit of CTI Molecular Imaging, Inc. , announced today that the U.S. Patent and Trademark Office has granted CPS an apparatus patent in connection with the development of the PET/CT scanner. This patent complements the existing "methods patent" granted to CPS last year.

"We continue to lead in the development of PET imaging systems, including the dual modality PET/CT systems, and this patent adds to our history of significant innovations that have fundamentally changed molecular imaging," said Greg Brophy, President of CPS Innovations. "PET/CT continues to be the fastest growing segment of diagnostic imaging and the clinical data continues to demonstrate the fundamental improvement in diagnostic accuracy and disease management that is available to the clinician through the use of this technology."

Since the development of the PET/CT was initiated in 1993 at the University of Geneva by co-developers David Townsend, Ph.D., and Ronald Nutt, Ph.D., sales of PET/CT have grown to over 70% of new PET system deliveries.

"The advantage of a PET/CT system is that it combines metabolic function and anatomic structure to more accurately identify the precise location of abnormalities in the body," said Dr. Townsend, now a member of the faculty at the University of Tennessee. "An increasing number of studies show PET/CT to be more effective than PET or CT alone in the diagnosis and staging of various forms of cancer."

Since the introduction of the PET/CT at the Radiological Society of North America (RSNA) in November 2000, CPS has announced numerous innovations in its PET/CT systems and recently completed the installation of its 25th 16-slice PET/CT, an installed base for 16-slice technology that is greater than all other manufacturers combined.

"Our commitment is to expand the benefits of molecular imaging to the patient and to the medical community at large," said Brophy. "This latest milestone in achieving our second significant patent related to PET/CT is further evidence of this commitment and our long-standing investment in research and development in PET and molecular imaging."

About CPS Innovations:

CPS Innovations is the trade name for CTI PET Systems, Inc., a joint venture between CTI Molecular Imaging, Inc. and Siemens Medical Solutions USA, Inc. CPS develops and manufactures PET scanners and other imaging technology, which it sells through distributors, including Siemens Medical Solutions USA, Inc., CTI Molecular Imaging, Inc., Hitachi Medical Systems of America, Inc, and Toshiba Medical Systems Corporation Japan.

About CTI:

CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, neurological disorders and cardiac disease. Additional information is available at:

About PET and PET/CT:

PET images the biology of diseases at the molecular level, often before anatomic changes are visible or, in some cases, before symptoms appear. Diseases are biological processes and it is these processes that PET examines. PET/CT is a new imaging technology that combines the biological examination of patients by PET with the CT images of the body's structural detail. PET/CT technology improves the diagnostic accuracy and treatment management of patients by providing surgeons, radiation oncologists and other physicians precise anatomical landmarks associated with the disease condition as determined by PET.

PET's whole-body imaging capability helps physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed. Recent published clinical trials have shown that in a wide array of cancers, the use of PET has caused the treatment to be changed for 15 to 50% of patients, depending on the specific clinical question. In addition, PET and PET/CT provide both the patient and their physician with a degree of certainty that is often unavailable through other imaging methods.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding the business of CTI Molecular Imaging, Inc. ("CTI") that are not historical facts are "forward- looking statements" that involve risks and uncertainties. Further information regarding such risks and uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2002, Quarterly Reports on Form 10-Q, and in other reports CTI files with the SEC. CTI undertakes no obligation to update or revise any forward-looking statements.

CTI Molecular Imaging, Inc.

CONTACT: Michael A. Lawless of CTI Molecular Imaging, Inc.,+1-865-218-2000

Read at

comments powered by Disqus